EFFECTIVENESS OF COMBINED INDUCTION CHEMOTHERAPY AND RADIOTHERAPY IN ADVANCED NASOPHARYNGEAL CARCINOMA

被引:93
作者
DIMERY, IW
PETERS, LJ
GOEPFERT, H
MORRISON, WH
BYERS, RM
GUILLORY, C
MCCARTHY, K
WEBER, RS
HONG, WK
机构
[1] UNIV TEXAS, MD ANDERSON CANC CTR, DEPT THORAC HEAD & NECK MED ONCOL, HOUSTON, TX 77025 USA
[2] UNIV TEXAS, MD ANDERSON CANC CTR, DEPT HEAD & NECK SURG, HOUSTON, TX 77025 USA
[3] UNIV TEXAS, MD ANDERSON CANC CTR, DIV RADIOTHERAPY, HOUSTON, TX 77025 USA
关键词
D O I
10.1200/JCO.1993.11.10.1919
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: This prospective trial was conducted with the goal of achieving an improvement in both overall and progression-free survival in previously untreated patients with stage IV nasopharyngeal carcinoma who received an induction chemotherapy regimen of fluorouracil (5-FU) and cisplatin followed by radiotherapy. Patients and Methods; From January 1985 to January 1990, 47 patients with T1-4N2-3M0 squamous cell carcinoma of the nasopharynx were treated at The University of Texas M.D. Anderson Cancer Center with two to three cycles of 5-FU (1,000 mg/m2 continuous infusion per day × 5 days) plus cisplatin (100 mg/m2 continuous infusion on day 1 only) followed by radiotherapy using the conventional time/dose schedule. Results: The response rate to chemotherapy was 93.2% (20.5% complete response [CR]; 72.7% partial response [PR]), and the overall CR rate after radiotherapy was 86%. With a median follow-up period of 53 months, the 2-, 4-, and 6-year survival rates were 80%, 71.6%, and 67.4%; the overall treatment failure rate was 27%. Treatment was well tolerated and without significant acute or chronic toxic effects. Conclusion: The results of this prospective study demonstrate that 5-FU plus cisplatin followed by radiotherapy can induce a durable remission in a high proportion of patients with poor-prognosis stage IV nasopharyngeal carcinoma.
引用
收藏
页码:1919 / 1928
页数:10
相关论文
共 60 条
[21]  
DROZ JP, 1986, P AN M AM SOC CLIN, V6, P139
[22]   CANCER OF THE NASOPHARYNX IN BRITISH-COLUMBIA [J].
FLORES, AD ;
DICKSON, RI ;
RIDING, K ;
COY, P .
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1986, 9 (04) :281-291
[23]  
FOUNTZILAS G, 1990, CANCER-AM CANCER SOC, V66, P1453, DOI 10.1002/1097-0142(19901001)66:7<1453::AID-CNCR2820660703>3.0.CO
[24]  
2-X
[25]   COMBINED RADIOTHERAPY AND CHEMOTHERAPY IN STAGE T3 AND T4 NASOPHARYNGEAL CARCINOMA IN CHILDREN [J].
GASPARINI, M ;
LOMBARDI, F ;
ROTTOLI, L ;
BALLERINI, E ;
MORANDI, F .
JOURNAL OF CLINICAL ONCOLOGY, 1988, 6 (03) :491-494
[26]   ANALYSIS OF PROGNOSTIC FACTORS AND PROPOSAL OF A NEW CLASSIFICATION FOR NASOPHARYNGEAL CANCER [J].
GRANDI, C ;
BORACCHI, P ;
MEZZANOTTE, G ;
SQUADRELLI, M ;
MARUBINI, E ;
MOLINARI, R .
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 1990, 12 (01) :31-40
[27]   THE PROMISING ROLE OF SAFE INITIAL NON-CISPLATIN-CONTAINING COMBINATION CHEMOTHERAPY IN NASOPHARYNGEAL TUMORS [J].
HILL, BT ;
PRICE, LA ;
MACRAE, KD .
CANCER INVESTIGATION, 1987, 5 (06) :517-522
[28]  
HO JHC, 1978, INT J RADIAT ONCOL, V4, P182
[29]  
HOPPE RT, 1976, CANCER, V37, P2605, DOI 10.1002/1097-0142(197606)37:6<2605::AID-CNCR2820370607>3.0.CO
[30]  
2-W